Despite great progress, real-world data that could be better exploited to research and improve healthcare systems, services and treatments, for the benefit of patients.

In a weeklong groundbreaking study-a-thon with the IMI EHDEN consortium, UMC researchers found longitudinal health data could boost preliminary analysis of drug-event combinations.

Real-world data is a rich source of evidence for pharmacovigilance, but there are challenges yet to be faced before unlocking its true potential as a resource.